Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Income towards Parent Company (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Income towards Parent Company for 7 consecutive years, with -$20.3 million as the latest value for Q4 2025.

  • Quarterly Income towards Parent Company fell 22.73% to -$20.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$74.9 million through Dec 2025, down 669.97% year-over-year, with the annual reading at -$74.9 million for FY2025, 669.97% down from the prior year.
  • Income towards Parent Company for Q4 2025 was -$20.3 million at Fulcrum Therapeutics, down from -$19.6 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $55.4 million in Q2 2024, with the low at -$34.1 million in Q2 2022.
  • Average Income towards Parent Company over 5 years is -$18.6 million, with a median of -$22.6 million recorded in 2021.
  • The sharpest move saw Income towards Parent Company skyrocketed 332.98% in 2024, then crashed 131.22% in 2025.
  • Over 5 years, Income towards Parent Company stood at -$23.5 million in 2021, then fell by 11.29% to -$26.1 million in 2022, then grew by 5.28% to -$24.8 million in 2023, then soared by 33.07% to -$16.6 million in 2024, then decreased by 22.73% to -$20.3 million in 2025.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at -$20.3 million, -$19.6 million, and -$17.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.